Peroxisome Proliferator‐Activated Receptor α Activation Suppresses Cytochrome P450 Induction Potential in Mice Treated with Gemfibrozil
Authors:
Open Access
- 4 April 2017
- journal article
- research article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 121 (3) , 169-174
Abstract
Gemfibrozil, a peroxisome proliferator‐activated receptor α (PPARα) agonist, is widely used for hypertriglyceridaemia and mixed hyperlipidaemia. Drug–drug interaction of gemfibrozil and other PPARα agonists has been reported. However, the role of PPARα in cytochrome P450 (CYP) induction by fibrates is not well known. In this study, wild‐type mice were first fed gemfibrozil‐containing diets (0.375%, 0.75% and 1.5%) for 14 days to establish a dose–response relationship for CYP induction. Then, wild‐type mice and Pparα‐null mice were treated with a 0.75% gemfibrozil‐containing diet for 7 days. CYP3a, CYP2b and CYP2c were induced in a dose‐dependent manner by gemfibrozil. In Pparα‐null mice, their mRNA level, protein level and activity were induced more than those in wild‐type mice. So, gemfibrozil induced CYP, and this action was inhibited by activated PPARα. These data suggested that the induction potential of CYPs was suppressed by activated PPARα, showing a potential role of this receptor in drug–drug interactions and metabolic diseases treated with fibrates.Keywords
Funding Information
- National Natural Science Foundation of China (81273582, 81302848)
- National Cancer Institute
- National Institutes of Health
- Ningbo University
This publication has 30 references indexed in Scilit:
- Direct Transcriptional Regulation of Human Hepatic Cytochrome P450 3A4 (CYP3A4) by Peroxisome Proliferator–Activated Receptor Alpha (PPARα)Molecular Pharmacology, 2013
- Seasonal Variation in Blood Drug Concentrations and a Potential Relationship to Vitamin DDrug Metabolism and Disposition, 2011
- Combination therapy of statins and fibrates in the management of cardiovascular riskCurrent Opinion in Lipidology, 2009
- Perfluorocarboxylic Acids Induce Cytochrome P450 Enzymes in Mouse Liver through Activation of PPAR-α and CAR Transcription FactorsToxicological Sciences, 2008
- Development and full validation of six inhibition assays for five major cytochrome P450 enzymes in human liver microsomes using an automated 96-well microplate incubation format and LC–MS/MS analysisJournal of Pharmaceutical and Biomedical Analysis, 2007
- Significance of the Minor Cytochrome P450 3A IsoformsClinical Pharmacokinetics, 2006
- GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONSDrug Metabolism and Disposition, 2006
- Gemfibrozil and Its Glucuronide Inhibit the Organic Anion Transporting Polypeptide 2 (OATP2/OATP1B1:SLC21A6)-Mediated Hepatic Uptake and CYP2C8-Mediated Metabolism of Cerivastatin: Analysis of the Mechanism of the Clinically Relevant Drug-Drug Interaction between Cerivastatin and GemfibrozilThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Regulation of CYP2C11 by Dehydroepiandrosterone and Peroxisome Proliferators: Identification of the Negative Regulatory Region of the GeneMolecular Pharmacology, 2003
- Regulation of cytochrome P450 (CYP) genes by nuclear receptorsBiochemical Journal, 2000